Redwire Corporation vs ResMed Inc. — how do they compare? Redwire Corporation trades at $8.99 (market cap $2.25B), while ResMed Inc. trades at $193.21 (market cap $28.40B). The key difference: ResMed Inc. is far larger — about 12.6× Redwire Corporation's market cap, and ResMed Inc. pays a 1.23% dividend while Redwire Corporation pays none. Which is the better fit depends on your goals.
| RDW | RMD | |
|---|---|---|
Market Cap | $2.25B | $28.40B |
Sector | Technology | Health |
52-Week High | $25.90 | $293.73 |
52-Week Low | $5.06 | $182.82 |
Enterprise Value | $2.31B | $27.58B |
Dividend Yield | — | 1.23% |
Signals from Pluang's Aura AI — not financial advice
Redwire (RDW) trades at $8.60, down 1.78% with a bearish technical signal despite oversold RSI readings. The company shows strong revenue growth potential with a record $492 million backlog and a 1.92 book-to-bill ratio, but faces significant profitability challenges with a net income margin of -80.9% and consecutive earnings misses. Recent expansions in Indiana and Alabama highlight operational growth amid substantial cash burn from operations.
The stock presents a high-risk, high-reward opportunity with an 80% analyst buy rating and a $19.00 consensus price target implying over 120% upside. However, persistent losses, negative cash flow from operations, and potential dilution from a $500 million ATM offering pose substantial risks to near-term shareholder value.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →